Correction of neutropenia associated with chronic lymphocytic leukaemia following treatment with granulocyte-macrophage colony-stimulating factor
- PMID: 2031965
- DOI: 10.1007/BF01714981
Correction of neutropenia associated with chronic lymphocytic leukaemia following treatment with granulocyte-macrophage colony-stimulating factor
Abstract
A patient with chronic lymphocytic leukaemia (CLL) and severe persisting neutropenia due to marrow infiltration of his leukaemia, developed bilateral Legionella pneumophila pneumonia for which he was treated with erythromycin, rifampin and ciprofloxacin. To increase the number of circulating polymorphonuclear neutrophils, the patient was treated with recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) at a dose of 2 micrograms protein/kg bodyweight s.c./12 h. GM-CSF therapy resulted in a sustained rise of the neutrophil count from the fifth day of treatment onwards, without showing an effect on the number of circulating leukemic cells. The patient completely recovered from his pneumonia. It is suggested that the rise of the neutrophil count, due to GM-CSF, contributed to the improvement of the infection of this patient. Our observation illustrates that GM-CSF can be given safely to CLL-patients and that it can be used effectively in CLL patients with severe bacterial infections to restore neutropenia.
Similar articles
-
Effect of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) on chemotherapy-induced myelosuppression in patients with chronic lymphocytic leukemia: a crossover study.Leuk Lymphoma. 1997 May;25(5-6):503-8. doi: 10.3109/10428199709039038. Leuk Lymphoma. 1997. PMID: 9250821 Clinical Trial.
-
Long-term treatment with GM-CSF in patients with chronic lymphocytic leukemia and recurrent neutropenic infections.Leuk Lymphoma. 1998 Dec;32(1-2):165-74. doi: 10.3109/10428199809059257. Leuk Lymphoma. 1998. PMID: 10037012 Clinical Trial.
-
Case report: Granulocyte-macrophage colony-stimulating factor sargramostim did not rescue the neutrophil phenotype in two patients with JAGN1-mutant severe congenital neutropenia.Front Immunol. 2024 Sep 2;15:1373495. doi: 10.3389/fimmu.2024.1373495. eCollection 2024. Front Immunol. 2024. PMID: 39286252 Free PMC article.
-
[GM-CSF and G-CSF: cytokines in clinical application].Schweiz Med Wochenschr. 1991 Mar 23;121(12):397-412. Schweiz Med Wochenschr. 1991. PMID: 1709294 Review. German.
-
Role of G-CSF GM-CSF in the management of infections in preterm newborns: an update.Early Hum Dev. 2014 Sep;90 Suppl 2:S15-7. doi: 10.1016/S0378-3782(14)50005-9. Early Hum Dev. 2014. PMID: 25220119 Review.
Cited by
-
Successful short-term treatment with granulocyte-macrophage colony-stimulating factor of neutropenia due to cytotoxic chemotherapy of chronic lymphocytic leukemia.Ann Hematol. 1991 Dec;63(6):333. doi: 10.1007/BF01709657. Ann Hematol. 1991. PMID: 1756194 No abstract available.
-
Current approaches to the treatment and management of chronic lymphocytic leukaemia.Drugs. 1994;47 Suppl 6:1-9. doi: 10.2165/00003495-199400476-00003. Drugs. 1994. PMID: 7525184 Review.
-
Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.Drugs. 1992 Apr;43(4):516-560. doi: 10.2165/00003495-199243040-00008. Drugs. 1992. PMID: 28421558